The Biopharmaceutical Development Program (BDP) at Frederick National Laboratory is engineering cells into cancer...
Five new projects led by Frederick National Laboratory for Cancer Research (FNL) scientists have earned Laboratory...
The success of today’s COVID-19 vaccines has given medical nanotechnology a long-awaited boost, with a renewed interest...

All News

[Apply]
Category
Date Posted Range

Looking Back, Looking Ahead: 2022’s AI Symposium Charted Paths for Cancer Research Progress

Bioinformatics and Computational Science, Cancer Data Science InitiativesPosted 2/2/2023
Last year, some of the world’s top leaders in the field came together to discuss the progress of artificial intelligence (AI) applications in cancer research and clinical care at a scientific symposium hosted by Hood College and Frederick National Laboratory (FNL). It was one of several large scientific gatherings in Frederick in 2022 with implications for the new year…

Encephalitis vaccine does well in early clinical trial; commercial development pending

Vaccine Clinical Materials ProgramPosted 12/21/2022
Commercial development of a vaccine against three types of mosquito-borne equine encephalitis viruses — which are classified as potential biological warfare agents and can be fatal in humans — has begun following a government-led phase I clinical trial conducted with materials produced by the Frederick National Laboratory’s Vaccine Clinical Materials Program. No therapies…

Partnership trainees embrace opportunity for hands-on experience and opt for extended time in FNL laboratories 

Partnership Development OfficePosted 12/19/2022
Undergraduate and graduate students from academic institutions that partner with the Frederick National Laboratory for Cancer Research gained laboratory experience through the Partnership Trainee Program 2022 summer session, which this year added the Morehouse School of Medicine and the program’s first medical student trainee. “By welcoming our first medical student, we…

Frederick National Laboratory produces CAR T-cell immunotherapies for pediatric cancer clinical trials

Biopharmaceutical Development ProgramPosted 11/15/2022
The Biopharmaceutical Development Program (BDP) at Frederick National Laboratory is engineering cells into cancer-killers that are being used to treat children and young adults participating in early-phase pediatric cancer trials. The treatment is called chimeric antigen receptor (CAR) T cell therapy. CAR T cells are a type of white blood cell that has been removed…

Real-world studies indicate NSAIDs improve lung cancer survival

Ethan Dmitrovsky, M.D.Posted 11/8/2022
Common drugs for controlling pain and inflammation – such as aspirin and ibuprofen – improved overall lung cancer survival by a statistically significant margin in a long-term study of patient medical records. This finding called for more definitive randomized clinical trials. Use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with a survival rate of 29.7…

Renowned FNL scientist joins late father-in-law and world leaders as member of American Academy of Arts and Sciences

Basic Science ProgramPosted 11/2/2022
Upon hearing earlier this year that she was elected to the prestigious American Academy of Arts and Sciences, cancer scientist Mary Carrington wished she could share the news with her beloved late father-in-law, a former law school dean at Duke. She had only discovered Paul Carrington’s academy membership after he died last year, when she and her husband found the…

Annual Technology Showcase to spotlight collaboration opportunities with NCI and FNL

Partnership Development OfficePosted 8/18/2022
The National Cancer Institute and Frederick National Laboratory for Cancer Research will hold the annual Technology Showcase on Wednesday, Sept. 7 in a hybrid format to welcome in-person attendees as well as remote participants from around the United States and the world. The event is scheduled from noon to 5:30 pm ET at the FNL’s Advanced Technology Research Facility in…

BIO International Convention 2022: Pursuing the mission of the Frederick National Laboratory in San Diego

Partnership Development OfficePosted 8/4/2022
Pursuing future partners and better weather, the Frederick National Laboratory for Cancer Research (FNL) recently attended the BIO 2022 International Convention in San Diego. This convention is one of the largest biotech partnering events internationally, with over 3,000 foreign and domestic companies represented at this year’s week-long June event. This setting created an…

Five new innovative projects awarded LDER funding

Laboratory-Directed Exploratory Research, Cancer Data Science Initiatives, AIDS and Cancer Virus Program, Basic Science ProgramPosted 7/21/2022
Five new projects led by Frederick National Laboratory for Cancer Research (FNL) scientists have earned Laboratory Directed Exploratory Research (LDER) funding for the upcoming fiscal year. The LDER program, which was modeled after the U.S. Department of Energy’s Laboratory Directed Research and Development program, provides FNL scientists the opportunity to compete for…

Hood College symposium to explore artificial intelligence in cancer research and clinical care

Cancer Data Science Initiatives, Partnership Development OfficePosted 7/7/2022
Some of the world’s top scientific leaders in the field will highlight the current progress of artificial intelligence (AI) applications in cancer research and clinical care at a scientific symposium hosted by Hood College in partnership with the Frederick National Laboratory for Cancer Research, September 2022. Cancer researchers are invited to attend the conference…